Intuitive Surgical, Inc. (OQ:ISRG)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
See Regulatory Filings on SEC
Company Contact
Address: 1020 Kifer Rd
SUNNYVALE CA 94086-5301
Tel: N/A
IR: See website
Key People
Lonnie M. Smith
Independent Chairman of the Board
Gary S. Guthart
President, Chief Executive Officer, Director
Marshall L. Mohr
Chief Financial Officer, Senior Vice President
Salvatore J. Brogna
Chief Operating Officer, Executive Vice President
Myriam J. Curet
Executive Vice President, Chief Medical Officer
David J. Rosa
Executive Vice President, Chief Commercial Officer
Mark J. Meltzer
Senior Vice President, Chief Compliance Officer, General Counsel
Jamie E. Samath
Vice President, Corporate Controller, and Principal Accounting Officer
Business Overview
Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company's da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon's hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition (HD) vision. Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company's instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.
Financial Overview
For the fiscal year ended 31 December 2018, Intuitive Surgical, Inc. revenues increased 19% to $3.72B. Net income before extraordinary items increased 14% to $1.13B. Revenues reflect U.S. segment increase of 15% to $2.63B, OUS segment increase of 28% to $1.09B. Net income was partially offset by Selling gen and exp increase of 19% to $808.2M (expense), Research and development Balancing increase of 25% to $341.9M (expense).
Employees: 5,527 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $59,734M as of Dec 31, 2018
Annual revenue (TTM): $3,724M as of Dec 31, 2018
EBITDA (TTM): $1,378M as of Dec 31, 2018
Net annual income (TTM): $1,128M as of Dec 31, 2018
Free cash flow (TTM): $982.20M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 114,488,602 as of Jan 18, 2019
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization